Abstract 49P
Background
Numb is a protein involved in asymmetric cell division determining cell fate across various research fields such as developmental neurobiology and cancer biology; however, its role remains poorly understood regarding brain metastases formation specifically within lung adenocarcinoma (LUAD).
Methods
In our previous study, five potential biomarkers for brain metastasis (BM) were identified using proteomic comparison of brain metastatic H1975-BrM cells and parent H1975 cells. We utilized the Cancer Genome Atlas Program (TCGA) database to analyze five genes expression at the level of mRNA in LUAD. Univariate and multivariate analyses were used to select independent risk factors that affect the prognosis of LUAD, and a nomogram model was established. The relationship between NUMB expression and LUAD immune infiltration was analyzed using TIMER, GEPIA database and TCGA data sets. In addition, clinical validation was performed using immunohistochemical (IHC) staining of lung tumor tissue from patients (n = 50) and investigated the relationship between NUMB and clinicopathology and prognosis in LUAD. The q-PCR and Western-blot assays were used to validate the expression of NUMB in vitro.
Results
After analyzing the prognostic value of those 5 differentially expressed genes, NUMB was the only gene associated with multiple prognostic indicators in LUAD patients using TCGA public database. Analysis of GEPIA datasets revealed that high NUMB expression in LUAD tissues correlates with poor patient survival. Multivariate analysis showed that Pathologic T stage, N stage, and high level of NUMB protein were independent prognostic factors of overall survival in patients with LUAD. These factors were used to construct the nomogram model. The analysis of TIMER, GEPIA database and TCGA data sets showed that the expression level of NUMB was negatively correlated with B cells, NK cells and Cytotoxic cells. Furthermore, NUMB was highly expressed in brain metastatic H1975-BrM cell line.
Conclusions
Our findings demonstrate that NUMB serves as an independent potential prognostic biomarker implicated not only in immune infiltration of LUAD, but also closely correlates with BM development.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract